Navigation Links
Cambrex Reports Second Quarter of 2011 Results
Date:8/2/2011

tion of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.   CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended June 30, 2011 and 2010(in thousands)20112010% of% ofAmountSalesAmountSalesGross Sales

$

67,484$

57,403Commissions, Allowances and Rebates523376Net Sales66,96157,027Other1,4211,190Net Revenues68,38258,217Cost of Goods Sold49,32573.1%40,28470.2%Gross Profit19,05728.2%17,93331.2%Operating ExpensesSelling, General and Administrative Expenses9,19113.6%8,18414.3%Research and Development Expenses2,5723.8%2,8414.9%Total Operating Expenses11,76317.4%11,02519.2%Operating Profit7,29410.8%6,90812.0%Other Expenses/(Income):Interest Expense, net6051,171Other (Income)/Expenses, net(282)14Equity in Losses of Partially-Owned Affiliate303-Income Before Income Taxes6,6689.9%5,72310.0%Provision for Income Taxes1,9112,057Income fro
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cambrex Reports Third Quarter 2010 Results
2. Cambrex Reports Fourth Quarter and Full Year 2009 Results
3. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
4. Cambrex Reports First Quarter 2009 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports Third Quarter 2008 Results
7. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
8. Gen-Probe Reports Financial Results for the Second Quarter of 2011
9. Neurocrine Biosciences Reports Second Quarter 2011 Results
10. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
11. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... 2009 , , ARVADA, Colo., June 16 ... and responsibility to our shareholders, is addressing our recent ... Finance 2009, a Biotechnology, Medical Devices, and world public ... 4-5. , , Pharma Finance is an international ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a ... oncology therapeutics for the treatment of solid and hematologic cancers, ... will be presenting at the Jefferies 3rd Annual Healthcare Conference ... 17, 2009. , , The live webcast of this ...
... SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a,Shanghai-based ... facility in Shanghai has passed the audit from a ... are praised,for providing good facilities and programs for the ... The inspection and audit took place in May. ...
Cached Biology Technology:GeneThera Extends its Reach Overseas 2Sundia's Animal Facility Passed Client and Government Inspection 2
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (UK) are to investigate how lethal viruses attack differently sized ... the door to new methods of pest control. The project, ... grain-infesting Indian meal moth ( Plodia interpunctella ) and a ... and sometimes not. Dr Steve Sait from the University ...
... Virginia Tech released today the results of a new rating ... the risk of concussions. One currently manufactured helmet received ... helmets received the very good "4-star" rating. ... first time researchers have provided the public with comparative test ...
... Palo Alto, CA Accurately calculating the amount of ... bringing products to our doorsteps is nearly impossible, but ... a commentary published online this week by Proceedings of ... Ken Caldeira and Steven Davis commend the work of ...
Cached Biology News:No safety in numbers for moths and butterflies 2Virginia Tech announces football helmet ratings for reducing concussion risk 2Virginia Tech announces football helmet ratings for reducing concussion risk 3Virginia Tech announces football helmet ratings for reducing concussion risk 4Consumption, carbon emissions and international trade 2
... , Coated Capture Antibody: 12 x 8-well strips, ... mL of 2X concentrate , Beta Amyloid ... , Lyophilized Standard Diluent: 3 mL , Primary ... Antibody-HRP: 30 microL of concentrate , OPD Substrate: ...
Human Cell Line Slides...
Request Info...
HSV 1 IgM...
Biology Products: